Cheaper anti-can­cer drugs to hit mar­ket

Shanghai Daily - - TOP NEWS - (Xin­hua)

PAY­MENT stan­dards for 17 types of anti-can­cer drugs newly in­cluded in China’s health care se­cu­rity sys­tem, on aver­age, are 56.7 per­cent lower than their re­tail prices, ac­cord­ing to Na­tional Health Care Se­cu­rity Ad­min­is­tra­tion yes­ter­day.

Pa­tients can be ex­pected to pur­chase these anti-can­cer drugs at lower prices by late Novem­ber, the ad­min­is­tra­tion said.

Xiong Xian­jun, an of­fi­cial with the ad­min­is­tra­tion, said these 17 anti-can­cer drugs, deal­ing with solid tu­mors and hema­to­log­i­cal neo­plasms, are clin­i­cally nec­es­sary, ther­a­peu­ti­cally ef­fec­tive and ur­gently needed by in­sur­ance par­tic­i­pants.

Pay­ment stan­dards for most of the im­ported drugs are, on aver­age, 36 per­cent lower than mar­ket prices in sur­round­ing coun­tries and re­gions, sig­nif­i­cantly re­duc­ing the bur­den of an­ti­cancer drug users.

Ne­go­ti­a­tion for the prices kicked off in June, and the 17 drugs were se­lected and in­cluded on China’s med­i­cal in­sur­ance re­im­burse­ment list through ex­pert re­view and vot­ing.

A to­tal of 10 drugs came into the mar­ket af­ter 2017. Fac­ing their pro­longed patent terms, the ne­go­ti­a­tion was tough.

This round of ne­go­ti­a­tion was clin­i­cal value-ori­ented, en­cour­aged in­no­va­tion, and in­sisted on be­ing just, fair and open, said Xiong.

He added that a triple win was achieved be­tween in­sur­ance par­tic­i­pants, med­i­cal in­sur­ance au­thor­i­ties and en­ter­prises.

Newspapers in English

Newspapers from China

© PressReader. All rights reserved.